Pages with the fewest revisions

Jump to navigation Jump to search

Showing below up to 50 results in range #51 to #100.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Cutaneous squamous cell carcinoma - null regimens‏‎ (1 revision)
  2. Pancreatic cancer, BRCA-mutated - null regimens‏‎ (1 revision)
  3. Testosterone cypionate‏‎ (1 revision)
  4. Donafenib (Zepsun)‏‎ (1 revision)
  5. Vonoprazan (Takecab)‏‎ (1 revision)
  6. Chronic lymphocytic leukemia - null regimens‏‎ (1 revision)
  7. University of Arizona Hematology Oncology Fellowship‏‎ (1 revision)
  8. Autologous stem cells‏‎ (1 revision)
  9. Domperidone (Motilium)‏‎ (1 revision)
  10. Nogapendekin alfa inbakicept (Anktiva)‏‎ (1 revision)
  11. Aumolertinib (Amelie)‏‎ (1 revision)
  12. Clobetasol‏‎ (1 revision)
  13. Allogeneic stem cells‏‎ (1 revision)
  14. Exagamglogene autotemcel (Casgevy)‏‎ (1 revision)
  15. Congenital thrombotic thrombocytopenic purpura‏‎ (1 revision)
  16. Rituximab-rixi (Riximyo)‏‎ (1 revision)
  17. Venous thromboembolism - null regimens‏‎ (1 revision)
  18. Polycythemia vera - null regimens‏‎ (1 revision)
  19. Paroxysmal nocturnal hemoglobinuria - null regimens‏‎ (2 revisions)
  20. Bismuth subcitrate‏‎ (2 revisions)
  21. Rituximab-rixa (Rixathon)‏‎ (2 revisions)
  22. CARv3-TEAM-E T-cells‏‎ (2 revisions)
  23. Mezigdomide (BMS-986348)‏‎ (2 revisions)
  24. Sitagliptin (Januvia)‏‎ (2 revisions)
  25. Doxycycline‏‎ (2 revisions)
  26. Gallium Ga 68 gozetotide (Locametz)‏‎ (2 revisions)
  27. Procedures‏‎ (2 revisions)
  28. St Elizabeth's Medical Center Hematology Oncology Fellowship‏‎ (2 revisions)
  29. Thrombocytopenia in liver disease - null regimens‏‎ (2 revisions)
  30. Fitusiran (ALN-AT3SC)‏‎ (2 revisions)
  31. Divarasib (GDC-6036)‏‎ (2 revisions)
  32. Hypereosinophilic syndrome - null regimens‏‎ (2 revisions)
  33. CART-EGFRvIII‏‎ (2 revisions)
  34. B-cell lymphoma of mucosa-associated lymphoid tissue - null regimens‏‎ (2 revisions)
  35. Ascorbic acid (Vitamin C)‏‎ (2 revisions)
  36. Bevacizumab-aybi (Aybintio)‏‎ (2 revisions)
  37. Bevacizumab-equi (Equidacent)‏‎ (2 revisions)
  38. University of Alabama Medical Center Hematology Oncology Fellowship‏‎ (2 revisions)
  39. Meperidine (Demerol)‏‎ (2 revisions)
  40. Follicular lymphoma - null regimens‏‎ (2 revisions)
  41. Valemetostat (Ezharmia)‏‎ (2 revisions)
  42. Cortisone‏‎ (2 revisions)
  43. Padeliporfin (Tookad)‏‎ (2 revisions)
  44. HemOnc.org LLC‏‎ (2 revisions)
  45. New York Presbyterian Hospital (Columbia Campus) Hematology Oncology Fellowship‏‎ (2 revisions)
  46. Miriplatin (Miripla)‏‎ (2 revisions)
  47. Immune thrombocytopenia - null regimens‏‎ (2 revisions)
  48. SUNY Health Science Center at Brooklyn Hematology Oncology Fellowship‏‎ (2 revisions)
  49. Subependymal giant cell astrocytoma - null regimens‏‎ (2 revisions)
  50. Nimustine (ACNU)‏‎ (2 revisions)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://hemonc.org/wiki/Special:FewestRevisions"